David D. Chang Sells 46,668 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) CEO David D. Chang sold 46,668 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the sale, the chief executive officer now owns 5,276,569 shares in the company, valued at $10,342,075.24. The trade was a 0.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Allogene Therapeutics Price Performance

ALLO stock traded down $0.01 on Friday, reaching $1.62. The company's stock had a trading volume of 10,012,923 shares, compared to its average volume of 3,094,591. Allogene Therapeutics, Inc. has a 52 week low of $1.32 and a 52 week high of $4.63. The company has a market capitalization of $351.97 million, a P/E ratio of -1.04 and a beta of 1.02. The firm has a fifty day moving average of $1.89 and a two-hundred day moving average of $2.28.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06. As a group, equities analysts expect that Allogene Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.

Remove Ads

Analyst Ratings Changes

ALLO has been the subject of several recent research reports. HC Wainwright lowered their target price on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday. Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Finally, Citizens Jmp raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a report on Friday, March 14th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Allogene Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $9.29.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System lifted its position in Allogene Therapeutics by 6.0% in the fourth quarter. California State Teachers Retirement System now owns 135,554 shares of the company's stock worth $289,000 after purchasing an additional 7,685 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Allogene Therapeutics by 18.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 270,559 shares of the company's stock worth $576,000 after purchasing an additional 41,753 shares during the period. Two Sigma Advisers LP lifted its position in Allogene Therapeutics by 12.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company's stock worth $5,756,000 after purchasing an additional 291,800 shares during the period. Rafferty Asset Management LLC lifted its position in Allogene Therapeutics by 15.9% in the fourth quarter. Rafferty Asset Management LLC now owns 367,445 shares of the company's stock worth $783,000 after purchasing an additional 50,499 shares during the period. Finally, Raiffeisen Bank International AG acquired a new stake in Allogene Therapeutics in the fourth quarter worth approximately $903,000. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).